Articles

The US Food and Drug Administration (FDA) approved ziv-aflibercept injection (Zaltrap, Sanofi US, Inc.) for use in combination with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. Read More ›

The US Food and Drug Administration (FDA) approved enzalutamide (Xtandi; Medivation, Inc., Astellas Pharma US, Inc.) for the treatment of patients with metastatic castration-resistant prostate cancer who had previously received docetaxel. Read More ›

Abiraterone acetate is a novel antiandrogen agent that has recently received an expanded indication for treatment in men with metastatic castration-resistant prostate cancer (mCRPC). Read More ›

The US Food and Drug Administration (FDA) approved pertuzumab (Perjeta; Genentech) for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2+ metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Read More ›

The US Food and Drug Administration (FDA) approved everolimus (Afinitor; Novartis Pharmaceuticals Corporation) for the treatment of postmenopausal women with advanced hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. Read More ›

The US Food and Drug Administration (FDA) approved carfilzomib (Kyprolis; Onyx Pharmaceuticals, Inc.) for the treatment of patients with multiple myeloma who have received at least 2 prior therapies and who have demonstrated disease progression. Read More ›

Chronic myeloid leukemia (CML) is a clonal proliferative disorder of the hematopoietic cells of myeloid lineage1-3 driven by a reciprocal translocation between chromosomes 9 and 22, resulting in the so-called Philadelphia (Ph) chromosome. Read More ›

Results from a study by the gastroenterologists at Arizona Digestive Health in Phoenix, AZ, that were presented at Digestive Disease Week show that patient use of a smartphone app significantly improves colonoscopy preparation. Read More ›

In a comprehensive investigation involving decades of published studies, Mayo Clinic researchers have determined that patients with inflammatory bowel disease (IBD) are at a 37% greater risk for melanoma. Read More ›

A new prostate cancer treatment drug, Xofigo (radium Ra 223 dichloride), has been approved by the FDA for use in men with symptomatic late-stage castration-resistant prostate cancer that has metastasized only to bones. Read More ›